Midostaurin approved for FLT3-mutated AML.

@article{Levis2017MidostaurinAF,
  title={Midostaurin approved for FLT3-mutated AML.},
  author={Mark J. Levis},
  journal={Blood},
  year={2017},
  volume={129 26},
  pages={
          3403-3406
        }
}
  • M. Levis
  • Published 29 June 2017
  • Biology, Chemistry
  • Blood
Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML. 
View on PubMed
ashpublications.org
151 Citations
Highly Influential Citations
8
Background Citations
40
Methods Citations
3

151 Citations

Citation Type

Citation Type

FLT3 inhibitors in acute myeloid leukemia
TLDR
Preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunit inib, tandutinib, quizartinIB, midostaurin, and gilteritinib are summarized.
Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis
  • Nichole Sly, Katie Gaspar
  • Biology, Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2019
TLDR
Midostaurin offers a novel strategy to treat both FLT3-mutated AML and advanced SM, and offers a therapeutic option for patients who have historically been difficult to treat.
Targeting FLT3 Mutations in Acute Myeloid Leukemia
TLDR
The use of FLT3 inhibitors in AML is reviewed in virtually all disease settings including induction, consolidation, maintenance, relapse, and after hematopoietic cell transplantation (HCT).
Midostaurin: A New Oral Agent Targeting FMS‐Like Tyrosine Kinase 3‐Mutant Acute Myeloid Leukemia
TLDR
Midostaurin is the first oral multitargeted TKI to improve overall survival in patients with FLT3‐mutant AML and represents an important addition to the limited armamentarium against AML.
Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
TLDR
Submicromolar efficacy of midostaurin in vitro and efficacy in vivo against wild‐type FLT3‐expressing AML cell lines and primary cells are demonstrated, and its effectiveness is compared with that of otherFLT3 inhibitors currently in clinical trials.
A review of FLT3 inhibitors in acute myeloid leukemia.
The role of targeted therapy in the management of patients with AML.
  • A. Perl
  • Biology, Medicine
    Blood advances
  • 2017
TLDR
A review of currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment in acute myeloid leukemia.
The role of targeted therapy in the management of patients with AML.
  • A. Perl
  • Biology, Medicine
    Hematology. American Society of Hematology. Education Program
  • 2017
TLDR
A review of currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment in acute myeloid leukemia.
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
TLDR
A cocrystal structure of FLT3 with a type I inhibitor, NCGC1481, that retained potent binding and activity againstFLT3 TKD and gatekeeper mutations is reported.
Akute myeloische Leukämie bei Erwachsenen
TLDR
The somatic molecular genetic testing at the time of initial diagnosis should encompass these before mentioned three genes next to the already routine testing of NPM1, CEBPA and FLT3-ITD.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
FLT3: ITDoes matter in leukemia
TLDR
This review summarizes the data on the molecular biology and clinical impact ofFLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.
The Future of Targeting FLT3 Activation in AML
TLDR
The distinct clinical phenotype of FLT3-mutated AML, historically and currently available therapeutics, mechanisms of resistance, ongoing trials, and future outlook at treatment strategies are discussed.
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
To the editor: FLT3-activating mutations are one of the most frequent genetic aberrations in acute myeloid leukemia (AML).[1][1] Internal tandem duplication (FLT3-ITD) mutations are associated with…
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
  • M. Levis
  • Biology, Medicine
    Hematology. American Society of Hematology. Education Program
  • 2013
TLDR
The preponderance of evidence suggests that transplantation in first remission, if possible, is probably the best option and Clinically useful FLT3 inhibitors are hopefully on the near horizon and are being studied in the context of current treatment paradigms.
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
TLDR
The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clinical FLT3 inhibitor.
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
TLDR
Combining lestaurtinib with intensive chemotherapy proved feasible in younger patients with newly diagnosed FLT3-mutated AML, but yielded no overall clinical benefit.
How I treat FLT3-mutated AML.
TLDR
How the management of FLT3-mutated acute myeloid leukemia reflects what the authors have learned about this subtype of the disease is discussed and how the management might change in the near future, with the emergence of clinically useful tyrosine kinase inhibitors.
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
TLDR
Midostaurin in combination with standard chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50 mg twice daily for 14 days.
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
  • T. Fischer, R. Stone, +14 authors F. Giles
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
The results suggest that midostaurin has hematologic activity in both patients with FLT3-mutant and wild-type AML, and the degree of clinical activity observed supports additional studies that combine midosturin and other agents such as chemotherapy especially in FLT 3-Mutant AML.
Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial
TLDR
The impact of age and midostaurin dose-adaptation after intensive induction chemotherapy on response and outcome in AML with FLT3 -ITD within the AMLSG 16-10 trial was evaluated.
...
1
2
3
4
5
...